Abstracts tagged "interleukins (IL)"

Abstract Number: 2878 • 2019 ACR/ARP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Philip Mease¹, Saima Chohan ², Ferran J. García Fructuoso ³, Alice Gottlieb ⁴, Richard C. Chou ⁵, Alan Mendelsohn ⁶, Rocco Ballerini ⁶ and Michael E. Luggen ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, AZ, USA, Phoenix, AZ, ³Hospital CIMA Sanitas, Barcelona, Spain, Barcelona, Spain, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁶Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁷Cincinnati Rheumatic Disease Study Group, Inc. and University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the…
Abstract Number: 950 • 2019 ACR/ARP Annual Meeting
Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease
Xiao-qing Liu¹, Xiaojie Liu ², Nalin Lai ³, Ting Cheng ¹, Chong Gao ⁴ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²Taiyuan University of Technology, Taiyuan, China (People's Republic), ³Shanxi Medical University, Taiyuan, China (People's Republic), ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Behcet’s disease (BD) is a chronic multisystemic disease characterized by muco-cutaneous and ocular manifestations, with central nervous system, vascular and/or gastro-intestinal involvement. Several studies…
Abstract Number: 2881 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Philip Mease¹, Laure Gossec ², Laura Coates ³, Alice B. Gottlieb ⁴, Deepak Assudani ⁵, Barbara Ink ⁵, Jason Coarse ⁶, Oscar Irvin-Sellers ⁵ and Dafna Gladman ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Philadelphia, PA, ⁵UCB Pharma, Slough, UK, Slough, United Kingdom, ⁶UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁷Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of…
Abstract Number: 1504 • 2019 ACR/ARP Annual Meeting
Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
Helena Marzo-Ortega¹, Corinne Miceli-Richard ², Sonja Gill ³, Marina Magrey ⁴, Paula Machado ⁵, Abhijit Shete ⁶, Jianyuan Wang ⁶, Susanne Rohrer ⁶ and Atul Deodhar ⁷, ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ²Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ³412 – 3075 Hospital Gate, Oakville, Canada, ⁴Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60%…
Abstract Number: 2909 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Spencer I Danto¹, Negin Shojaee ¹, Ravi Shankar P Singh ¹, Zorayr Manukyan ², Jessica Mancuso ¹, Elena Peeva ¹, Michael Vincent ¹ and Jean Beebe ¹, ¹Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, Cambridge, MA, ²Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, ..
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of rheumatoid arthritis (RA). Toll-like receptor (TLR) stimulation activates the innate immune system,…
Abstract Number: 1517 • 2019 ACR/ARP Annual Meeting
Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis
Iain McInnes¹, Dafna Gladman ², Atul Deodhar ³, Corinne Miceli-Richard ⁴, Peter Nash ⁵, Naveed Sattar ⁶, Nehal Mehta ⁷, Darren Asquith ⁸, Jianyuan Wang ⁹, Hanno Richards ⁹, Luminita Pricop ¹⁰ and Abhijit Shete ⁹, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Oregon Health & Science University, Portland, OR, ⁴Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ⁵University of Queensland, Brisbane, Queensland, Australia, ⁶Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁸Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Systemic inflammation may influence cardio-metabolic profiles and increases the risk of CV disorders in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients (pts)1. Treatment…
Abstract Number: 1523 • 2019 ACR/ARP Annual Meeting
Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
Alan Menter ¹, Zoe Draelos ², Jayme Heim ³, Jeff Parno ⁴, Alan Mendelsohn⁴, Stephen Rozzo ⁴ and Christopher Griffiths ⁵, ¹Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX, USA, Dallas, TX, ²Dermatology Consulting Services, High Point, NC, USA, High Point, NC, ³West Michigan Dermatology, Holland, MI, USA, Holland, MI, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody approved for the treatment of moderate-to-severe chronic plaque psoriasis. An inverse efficacy–body weight relationship has been…
Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Christopher T. Ritchlin¹, Arthur Kavanaugh², Joseph F. Merola³, Georg Schett⁴, Jose U. Scher⁵, Richard B. Warren⁶, Deepak Assudani⁷, Thomas Kumke⁸, Barbara Ink⁷ and Iain B. McInnes⁹, ¹University of Rochester Medical Centre, Rochester, NY, ²UC San Diego School of Medicine, La Jolla, CA, ³Brigham and Women's Hospital Harvard Medical School, Boston, MA, ⁴Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁵Department of Medicine, NYU Langone Medical Center, New York, NY, ⁶The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
Abstract Number: 2562 • 2018 ACR/ARHP Annual Meeting
Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis
Ana-Maria Orbai¹, Iain B. McInnes², Laura C. Coates³, M. Elaine Husni⁴, Dafna D Gladman⁵, Laure Gossec⁶, Luminita Pricop⁷, Olivier Chambenoit⁸, Xiangyi Meng⁸ and Philip J. Mease⁹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Glasgow, Glasgow, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Cleveland Clinic, Cleveland, OH, ⁵Toronto Western Research Institute and University of Toronto, Toronto, ON, Canada, ⁶Université Pierre et Marie Curie and Hôpital Pitié-Salpêtrière, Paris, France, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has demonstrated efficacy for patients with psoriatic arthritis (PsA) in multiple phase 3 clinical…
Abstract Number: 2563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial
Kim A Papp¹, Kenneth B. Gordon², Diamant Thaçi³, Akimichi Morita⁴, Melinda Gooderham⁵, Peter Foley^6,7,8, Ihab G. Girgis⁹, Sudeep Kundu⁹ and Subhashis Banerjee⁹, ¹Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Luebeck, Luebeck, Germany, ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵SKiN Centre for Dermatology, Queen’s University and Probity Medical Research, Peterborough, ON, Canada, ⁶The University of Melbourne, Melbourne, Australia, ⁷St Vincent’s Hospital Melbourne & Probity Medical Research, Melbourne, Australia, ⁸Skin & Cancer Foundation Inc, Melbourne, Australia, ⁹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986165, a potent and highly selective oral tyrosine kinase 2 inhibitor, inhibits signal transducer and activator of transcription (STAT)-dependent signalling pathways of interleukin-23 and…
Abstract Number: 2572 • 2018 ACR/ARHP Annual Meeting
Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning
Luminita Pricop¹, Corine Gaillez², Gregory Ligozio³, Xuan Zhu³ and David James³, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ²Novartis Pharma AG, Basel, Switzerland, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Subcutaneous secukinumab 150mg and 300mg are approved doses for the treatment of psoriatic arthritis (PsA) with the higher dose recommended for patients with anti-TNF inadequate…
Abstract Number: 142 • 2018 ACR/ARHP Annual Meeting
Peripheral CD4+CD25+Foxp3+T Regulatory Cells Absolutely Reduce in Patients with Systemic Lupus Erythematosus
Xiao-Qing Liu¹, Na-Lin Lai², Yanan Duan¹, Junwei Chen¹, Xiao-Feng Li³ and Chong Gao⁴, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ³Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: Regulatory T (Treg) cells, with the capacity to suppress immune responses, and effector T (Teff) cells, to promote inflammation, have been intensively studied in…
Abstract Number: 2577 • 2018 ACR/ARHP Annual Meeting
Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study
Anthony Turkiewicz¹, Amanda M. Gellett², Lisa Kerr², Julie Birt² and Jordi Gratacos³, ¹Rheumatology Associates, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN, ³Rheumatology, Hospital Parc Taulí, Sabadell - Barcelona, Spain
Background/Purpose: PsA is a chronic and complex inflammatory disease with both articular and extra-articular symptoms, including joint pain, enthesitis, dactylitis, fatigue, and skin and nail…
Abstract Number: 238 • 2018 ACR/ARHP Annual Meeting
IL Inhibitors Therapy in Rheumatic Diseases and the Risk of Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials
Jawad Bilal¹, Irbaz Bin Riaz², Adam Berlinberg³, Abdullah Alhifany⁴, Gilbert Ortega⁵ and Warda Faridi⁶, ¹University of Arizona, Tucson, AZ, ²Mayo Clinic, Richestor, MN, ³Department of Internal Medicine, University of Arizona, Tucson, AZ, ⁴Department of Pharmacy, University of Arizona, Tucson, AZ, ⁵Internal Medicine, University of Arizona, Tucson, Tucson, AZ, ⁶Department of Hematology/Oncology, University of Arizona, Tucson, AZ
Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitor therapy in patients with rheumatologic disorders is well known to increase the risk of malignancy. While the individual…
Abstract Number: 2582 • 2018 ACR/ARHP Annual Meeting
Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure
Atul A. Deodhar¹, Dafna D Gladman², Iain B. McInnes³, Filip van Den Bosch⁴, Abhijit Shete⁵, Ruquan You⁶, Samina Hussain⁷ and Jorge Safi⁸, ¹Oregon Health & Science University, Portland, OR, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁶Shanghai Novartis Trading Limited, Shanghai, China, ⁷Novartis Healthcare Private Limited, Hyderabad, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes IL-17A, is currently approved in >75 countries for use in psoriasis /psoriatic arthritis and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].